المؤلفون: McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, Berkowitz RL, Berry AC, Borody TJ, Brewer JH, Brufsky AM, Clarke T, Derwand R, Eck A, Eck J, Eisner RA, Fareed GC, Farella A, Fonseca SNS, Geyer CE, Gonnering RS, Graves KE, Gross KBV, Hazan S, Held KS, Hight HT, Immanuel S, Jacobs MM, Ladapo JA, Lee LH, Littell J, Lozano I, Mangat HS, Marble B, McKinnon JE, Merritt LD, Orient JM, Oskoui R, Pompan DC, Procter BC, Prodromos C, Rajter JC, Rajter J-J, Ram CVS, Rios SS, Risch HA, Robb MJA, Rutherford M, Scholz M, Singleton MM, Tumlin JA, Tyson BM, Urso RG, Victory K, Vliet EL, Wax CM, Wolkoff AG, Wooll V, Zelenko V

مصطلحات موضوعية: COVID-19, SARS-CoV-2, ambulatory treatment, anti-infective, anti-inflammatory, anticoagulant, antiplatelet agent, antiviral, corticosteroid, hospitalization, mortality, sequenced multidrug therapy, Drug Therapy, Combination, Humans, Leprostatic Agents, Pandemics, Telemedicine

Relation: http://hdl.handle.net/11375/26557; https://doi.org/10.31083/j.rcm.2020.04.264

الاتاحة: http://hdl.handle.net/11375/26557
https://doi.org/10.31083/j.rcm.2020.04.264